Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin icodec - Novo Nordisk

Next Previous
Drug Profile

Insulin icodec - Novo Nordisk

Alternative Names: 148-0287-A; AWIQLI; Insulin 287; LAI-287; Long-acting basal insulin analogue-287 - Novo-Nordisk; Long-acting-insulin-287 - Novo-Nordisk; NN-1436; NN-1956; NNC-0148-0000-0287; NNC0148-0287 C; OI 287GT

Latest Information Update: 16 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 16 Apr 2024 Novo Nordisk expects to receive marketing authorisation from the US FDA for insulin icodec during the third quarter of 2024
  • 04 Apr 2024 Novo Nordisk plans a phase III trial for Type 2 diabetes mellitus (Treatment-experienced) in USA, Bulgaria, Germany, India, Japan, Poland, Puerto Rico, South Africa and Spain (SC) (NCT06340854)
  • 21 Mar 2024 Novo Nordisk expects to receive marketing authorisation from the European Commission for Type 1 and 2 diabetes mellitus in the EU within approximately two months
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top